US2904573A - Ferrous citrate complex - Google Patents
Ferrous citrate complex Download PDFInfo
- Publication number
- US2904573A US2904573A US657042A US65704257A US2904573A US 2904573 A US2904573 A US 2904573A US 657042 A US657042 A US 657042A US 65704257 A US65704257 A US 65704257A US 2904573 A US2904573 A US 2904573A
- Authority
- US
- United States
- Prior art keywords
- iron
- ferrous
- complex
- parts
- diet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
Definitions
- This invention relates to a new therapeutically effective compound for providing a source of iron in the diet and more particularly relates to a new therapeutic compound in the nature of a ferrous salt of citric acid,
- ferrous compounds such as ferrous sulfate consistently causes some degree of digestive discomfort.
- a compound having the empirical formula Fe (C H O -10H O and the structural formula in which the ten molecules of water are bound by coordinate covalences may be prepared from citric acid or ferrous acid citrate by reacting either compound with the stoichiometric quantity of powdered iron required to produce triferrous dicitrate.
- the complex is a very slightly colored powder and is very stable to air oxidation, the ferrous content remaining substantially ungen is continued throughout the reaction and the mixture is stirred and heated to C. during a period of two hours and maintained at that temperature for an additional two or three hours.
- an additional 55.9 parts (1 mole) of reduced powdered iron is added and stirring is continued under nitrogen while maintaining the reaction temperature at 80 C. until the total reaction time is 24 hours.
- the mixture is suction-filtered whilehot.
- the filtered cake is washed with water until free from chloride ion and then three times with an equal volume of isopropanol.
- the product is dried at 50 C. for six hours.
- the yield is 650 parts (90% calculated as the decahydrate) of white crystalline material.
- the product so obtained is analyzed for carbon, hydrogen, and iron.
- T riferrous dicitrate decahydrate One hundred seventeen and four-tenths parts (0.445 mole) of the monoferrous acid citrate monohydrate obtained from Example 11 above is added to 500 parts of water, and air is displaced from the reaction kettle with nitrogen as described above. To this suspension is added 12.4 parts (0.223 mole) of powdered iron and the mixture is stirred and heated at 85 -90 C. for 24 hours. The product is filtered off, washed with water, then with acetone, and air dried. One hundred twenty-nine parts of a crystalline product similar to the product obtained in Example I is recovered. The product so obtained had the final analysis:
- the complex may be uniformly distributed in a suitable vehicle and formed into a tablet.
- Inert diluents or fillers are chosen which are chemically compatible with the complex. Satisfactory diluents include lactose, dextrose, sucrose, sodium chloride, glycine, kaolin and starch.
- a binder such as acacia, zein, tragacanth, gelatin, sodium carboxymethylcellulose, or methylcellulose and also, in order that a tablet may be readily prepared, that a lubricant such as magnesium stearate, zinc stearate, mineral oil, stearic acid, stearyl alcohol or monoand polyglycol esters also be intimately admixed with the filler and active agent.
- a lubricant such as magnesium stearate, zinc stearate, mineral oil, stearic acid, stearyl alcohol or monoand polyglycol esters also be intimately admixed with the filler and active agent.
- the above ingredients, including the complex may be formed into a tablet by thoroughly mixing the ingredients in a moist condition, granulating and compressing the mixture into tablets by conventional methods.
- Additives such as tricalcium citrate may be used alone or with inert diluents if it is desired to supply calcium along with the iron in
- a composition of matter in dosage unit form for oral administration effective as a source of iron in the diet which comprises a ferrous citrate complex having the formula Fe (C H O -1OH O in intimate admixture with an inert solid diluent.
- a process for the preparation of a triferrous dicitrate complex having associated therewith water of hydration comprising the steps of adding powdered iron to a suspension of monoferrous acid citrate in water and heating the mixture whereby the complex is formed and precipitated, and removing the precipitated complex.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
United States Patent FERROUS CITRATE COMPLEX No Drawing. Application May 6, 1957 Serial No. 657,042
3 Claims. (Cl. 260-439) This invention relates to a new therapeutically effective compound for providing a source of iron in the diet and more particularly relates to a new therapeutic compound in the nature of a ferrous salt of citric acid,
Heretofore, it has been the established practice to administer iron in the form of ferrous sulfate to provide a source of iron in the diet of humans where indicated. Supplemental sources of iron are frequently required by anemic, pregnant, and aged patients.
It has been frequently observed that the administration in the diet of ferrous compounds such as ferrous sulfate consistently causes some degree of digestive discomfort. Youm ans, Journal of the American Medical Association, volume 143, page 1252, 1950; summarized the undesirable features due to the addition of ferrous compounds in the diet by stating that patients undergoing such treatment traditionally complain of gastro-intestinal symptoms, nausea, cramps, diarrhea and epigastric distress from taking iron; but if the patients persist in continuing to take iron, the symptoms usually disappear, probably due to an acquired tolerance,
2,904,573 a e ted S pt.- 5, 5.9
ice
2 changed after six months of storage in air at ordinary temperatures in the absence of direct light. However, removal of the water by vacuum desiccation at elevated or room temperature results in spontaneous auto-oxidation of the complex with the conversion of the ferrous iron of the complex to the ferric state. The dehydrated compounds continue to oxidize to the ferric state when allowed to stand at room temperature even in the absence of light. The structure of thev dehydrated compound or of the mixture of compounds formed on dehydration is not known but X-ray diffraction patterns and chemical analysis show it to be an entirely different chemical entity from that of the hydrated material having the above formula.
The following examples are set forth for the purpose of illustrating the method of preparing the ferrous citrate complex and compositions of matter in dosage unit form according to this invention but are not to be construed as a limitation. All parts are given by weight unless otherwise indicated.
EXAMPLE I Triferrous dicitrate decahydrate In a reaction kettle equipped with a stirrer, reflux condenser, and gas inlet, tube reaching below the expected liquid level, is placed 420 parts 2 moles) of citric acid monohydrate and 2000 parts of water. The solution is stirred at room temperature while nitrogen is passed in, and when the'air is displaced from the kettle (about 30 minutes) 111.7 parts (2 moles) of reduced powdered iron is added rapidly. The introduction of nitro- Iron preparations in liquid form, and solutions of ferrous sulfate in particular, are offensive to taste. Ferrous compounds are unstable and are readily oxidized to the ferric form on exposure to the atmosphere.
It is an object of this invention to provide a stable, therapeutic compound in the nature of a ferrous salt of citric acid.
It is another objectof this invention to provide a stable, therapeutic compound containing all of the chemically bound iron in the ferrous state which upon oral administration is utilized normally without gastro-intestinal disturbances, constipation or diarrhea.
It is still another object of this invention to provide a new and improved therapeutic tablet effective by oral administration in providing a supplemental source of iron in the diet.
Other and further objects of this invention will be apparent from the description to follow, the examples and the appended claims.
It has now been discovered that a compound having the empirical formula Fe (C H O -10H O and the structural formula in which the ten molecules of water are bound by coordinate covalences, may be prepared from citric acid or ferrous acid citrate by reacting either compound with the stoichiometric quantity of powdered iron required to produce triferrous dicitrate. The complex is a very slightly colored powder and is very stable to air oxidation, the ferrous content remaining substantially ungen is continued throughout the reaction and the mixture is stirred and heated to C. during a period of two hours and maintained at that temperature for an additional two or three hours. When the reaction is completed, as indicated by the disappearance of unreacted iron particles, an additional 55.9 parts (1 mole) of reduced powdered iron is added and stirring is continued under nitrogen while maintaining the reaction temperature at 80 C. until the total reaction time is 24 hours.
At the end of this period, the mixture is suction-filtered whilehot. The filtered cake is washed with water until free from chloride ion and then three times with an equal volume of isopropanol. The product is dried at 50 C. for six hours. The yield is 650 parts (90% calculated as the decahydrate) of white crystalline material.
The product so obtained is analyzed for carbon, hydrogen, and iron.
Found, Theory for percent the decahydrate, percent Carbon 20.02 19. Hydrogen 4. 15 4. 17 Iron 23. 16 23. 08
The above analysis corresponds most closely to the decahydrate.
EXAMPLE II Monoferrous acid citrate monohydrate hundred twenty-one parts of the dry product is recovered. The product so obtained is analyzed for carbon, hydrogen, and iron.
T riferrous dicitrate decahydrate One hundred seventeen and four-tenths parts (0.445 mole) of the monoferrous acid citrate monohydrate obtained from Example 11 above is added to 500 parts of water, and air is displaced from the reaction kettle with nitrogen as described above. To this suspension is added 12.4 parts (0.223 mole) of powdered iron and the mixture is stirred and heated at 85 -90 C. for 24 hours. The product is filtered off, washed with water, then with acetone, and air dried. One hundred twenty-nine parts of a crystalline product similar to the product obtained in Example I is recovered. The product so obtained had the final analysis:
In employing the ferrous citrate complex of the present invention for the provision of a source of iron in the diet, the complex may be uniformly distributed in a suitable vehicle and formed into a tablet. Inert diluents or fillers are chosen which are chemically compatible with the complex. Satisfactory diluents include lactose, dextrose, sucrose, sodium chloride, glycine, kaolin and starch. It is desirable that a binder such as acacia, zein, tragacanth, gelatin, sodium carboxymethylcellulose, or methylcellulose and also, in order that a tablet may be readily prepared, that a lubricant such as magnesium stearate, zinc stearate, mineral oil, stearic acid, stearyl alcohol or monoand polyglycol esters also be intimately admixed with the filler and active agent. The above ingredients, including the complex, may be formed into a tablet by thoroughly mixing the ingredients in a moist condition, granulating and compressing the mixture into tablets by conventional methods. Additives such as tricalcium citrate may be used alone or with inert diluents if it is desired to supply calcium along with the iron in the tablet or formulation.
EXAMPLE IV Milligrams F3(C5H507)21OH20 Ca (C I-I O Dipotassium phosphate 50 Acacia 5O Magnesium stearate 30 Lactose -L EXAMPLE V F63(C5H507)2' Ca (C H O Dipotassium phosphate 100 Acacia 50 Magnesium stearate 3O Lactose 70 The novel ferrous citrate complex to which the present invention is directed, has been found to have value for the provision of a source of iron where the administration of this element in the diet is indicated and is particularly valuable for oral administration in the diet of anemic, pregnant, and aged individuals. 7 Since certain changes in carrying out the above process and certain modifications in the compositions which embody the invention may be made without departing from its scope, it is intended that all matter contained in the description shall be interpreted as illustrative and not in a limiting sense.
This application is a continuation-in-part of application Serial No. 617,943 filed October 24, 1956, now abancloned.
What is claimed is:
l. Triferrous dicitrate decahydrate.
2. A composition of matter in dosage unit form for oral administration effective as a source of iron in the diet which comprises a ferrous citrate complex having the formula Fe (C H O -1OH O in intimate admixture with an inert solid diluent.
3. A process for the preparation of a triferrous dicitrate complex having associated therewith water of hydration; comprising the steps of adding powdered iron to a suspension of monoferrous acid citrate in water and heating the mixture whereby the complex is formed and precipitated, and removing the precipitated complex.
References Cited in the file of this patent UNITED STATES PATENTS 2,621,201 Opfermann V Dec. 9, 1952
Claims (1)
1. TRIFERROUS DICITRATE DECAHYDRATE.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US657042A US2904573A (en) | 1957-05-06 | 1957-05-06 | Ferrous citrate complex |
CH5274457A CH367593A (en) | 1957-05-06 | 1957-11-16 | Process for the preparation of a ferrocitrate complex |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US657042A US2904573A (en) | 1957-05-06 | 1957-05-06 | Ferrous citrate complex |
Publications (1)
Publication Number | Publication Date |
---|---|
US2904573A true US2904573A (en) | 1959-09-15 |
Family
ID=24635617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US657042A Expired - Lifetime US2904573A (en) | 1957-05-06 | 1957-05-06 | Ferrous citrate complex |
Country Status (2)
Country | Link |
---|---|
US (1) | US2904573A (en) |
CH (1) | CH367593A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3091626A (en) * | 1960-06-20 | 1963-05-28 | Scherer Corp R P | Method of making ferrous citrate |
US4292324A (en) * | 1974-05-02 | 1981-09-29 | Aktiebolaget Draco | Aqueous zinc solutions for medical use |
US4400535A (en) * | 1980-01-17 | 1983-08-23 | Dr. Madaus & Co. | Acidic alkali citrate and compositions for adjusting the pH of urine |
US4575502A (en) * | 1982-10-22 | 1986-03-11 | National Research Development Corporation | Pharmaceutical compositions |
US4894455A (en) * | 1983-10-31 | 1990-01-16 | National Research Development Corporation | Pharmaceutically active zinc complexes |
US5028411A (en) * | 1984-04-19 | 1991-07-02 | National Research Development Corporation | Pharmaceutical compositions |
US5206265A (en) * | 1987-09-14 | 1993-04-27 | Schering Aktiengesellschaft | Iron citrate complex, process for its production, and its pharmaceutical |
USRE37534E1 (en) | 1982-10-22 | 2002-01-29 | Btg International Limited | Pharmaceutical compositions |
US20080033196A1 (en) * | 2006-08-04 | 2008-02-07 | Swee-Keng Goh | Metal carboxylate salts |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2621201A (en) * | 1949-09-13 | 1952-12-09 | Johann G W Opfermann & Sohn | Manufacture of ferro-calcium-citrate |
-
1957
- 1957-05-06 US US657042A patent/US2904573A/en not_active Expired - Lifetime
- 1957-11-16 CH CH5274457A patent/CH367593A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2621201A (en) * | 1949-09-13 | 1952-12-09 | Johann G W Opfermann & Sohn | Manufacture of ferro-calcium-citrate |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3091626A (en) * | 1960-06-20 | 1963-05-28 | Scherer Corp R P | Method of making ferrous citrate |
US4292324A (en) * | 1974-05-02 | 1981-09-29 | Aktiebolaget Draco | Aqueous zinc solutions for medical use |
US4400535A (en) * | 1980-01-17 | 1983-08-23 | Dr. Madaus & Co. | Acidic alkali citrate and compositions for adjusting the pH of urine |
US4575502A (en) * | 1982-10-22 | 1986-03-11 | National Research Development Corporation | Pharmaceutical compositions |
US4834983A (en) * | 1982-10-22 | 1989-05-30 | National Research Development Corporation | Pharmaceutical compositions |
US4861767A (en) * | 1982-10-22 | 1989-08-29 | National Research Corporation | Pharmaceutical compositions |
USRE37534E1 (en) | 1982-10-22 | 2002-01-29 | Btg International Limited | Pharmaceutical compositions |
US4894455A (en) * | 1983-10-31 | 1990-01-16 | National Research Development Corporation | Pharmaceutically active zinc complexes |
US5028411A (en) * | 1984-04-19 | 1991-07-02 | National Research Development Corporation | Pharmaceutical compositions |
US5206265A (en) * | 1987-09-14 | 1993-04-27 | Schering Aktiengesellschaft | Iron citrate complex, process for its production, and its pharmaceutical |
US20080033196A1 (en) * | 2006-08-04 | 2008-02-07 | Swee-Keng Goh | Metal carboxylate salts |
US7495117B2 (en) | 2006-08-04 | 2009-02-24 | Kemin Industries, Inc. | Metal carboxylate salts |
Also Published As
Publication number | Publication date |
---|---|
CH367593A (en) | 1963-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US2904573A (en) | Ferrous citrate complex | |
AT366050B (en) | METHOD FOR PRODUCING A HYDRATED CRYSTALLINE FORM OF THE SODIUM SALT OF AN OXIDE DERIVATIVE OF THE 7-AMINOTHIAZOLYL ACETAMIDOCEPHALOSPO RANIC ACID | |
JPH0532370B2 (en) | ||
US2848366A (en) | Non-hydrated ferrous fumarate and hematinic composition thereof | |
US2812344A (en) | Ferrous calcium citrate complex | |
US3830824A (en) | Physiological organic acid silver allantoinates | |
DE69810601T2 (en) | SOLID COMPOSITIONS CONTAINING ALKANOYL-L-CARNITINE MAGNESIUM CITRATE FOR ORAL ADMINISTRATION | |
US3478073A (en) | Preparation of anhydrous ferrous fumarate | |
FI71314C (en) | PROCEDURE FOR THE FRAMEWORK OF PROPERTY THERAPEUTIC BETA- (4,5-DIPHENYLOXAZOL-2-YL) PROPIONSYRAKALCIUMSALT | |
JPH0567638B2 (en) | ||
US3076830A (en) | Vanadium compounds | |
US2823166A (en) | Choline ascorbate, methods for producing same, and compositions thereof | |
EP0141267B1 (en) | Acid salts of valproic acid | |
DE944943C (en) | Process for the preparation of sodium perborate trihydrate | |
Kraus et al. | Reactions Of Strongly Electropositive Metals With Organic Substances In Liquid Ammonia Solution. Iv. Action Of The Alkali Metals On Triphenylmethyl And Its Compounds | |
US3298917A (en) | Antidiabetic nu-acylaliphaticsulfonamides | |
US2260870A (en) | Medicinal preparation | |
US3064010A (en) | Production of sodium isoascorbate monohydrate | |
DE1119249B (en) | Process for the production of an oxidation-resistant and ferric salt-free monoferrodicalcium citrate containing water of crystallization | |
BE542824A (en) | ||
US3840662A (en) | Method of treating atherosclerosis using 4-hydroxymethyl-1-keto-1,2-dihydrophthalazine or acid salts thereof | |
DE2033997A1 (en) | New alpha (p chlorophenoxy) isobutter acid derivatives | |
US2890233A (en) | Iron-containing organic compounds | |
US3117122A (en) | Schiff base of 4-amino-3-isoxazolidone and terephthalaldehyde | |
JPH062580B2 (en) | Boehmite-like aluminum hydroxide, its production method and oral phosphate adsorbent containing it |